Merck Experimental Oral Drug ‘Molnupiravir’ Could Reduce Risk of Death from Covid-19

PR PANGARAN – Based on the published preliminary clinical trial results, oral medication experimental Merck for Covid-19, molnupiravir can reduce about 50 percent of the chances hospitalized.

Not only that, oral medication from Merck This can also reduce the risk death for patients Covid-19 who have a serious illness.

Merck and its partner Ridgeback Biotherapeutics plan to seek US emergency use authorization for the pill Covid-19 as soon as possible and to submit applications to regulatory bodies worldwide.

Also Read: Link to Watch Love Bonds Friday October 1, 2021: Aldebaran Ready to Arrest Iqbal, Irvan Visits Sofia’s Grave

Due to the positive results, the Phase 3 trial was terminated early on the recommendation of an outside monitor.

“This will change the dialogue around how to manage Covid-19, ”Robert Davis, CEO Merck, told Reuters quoted PikiranRakyat-Pangandaran.com.

If allowed, molnupiravir, which is designed to insert errors into the genetic code of the virus, will be the first oral antiviral drug for Covid-19.

Also Read: The Biggest Fear of Every Zodiac: Leo is afraid of being forgotten, Libra is afraid of making the wrong decision

Rivals including Pfizer and Swiss pharmaceutical Roche Holding AG are racing to develop easy-to-use antiviral pills for Covid-19 but so far, only antibody cocktails – which must be administered intravenously – are approved to treat patients Covid-19 who are not hospitalized.

.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Trending